Trump Had Financial Stakes In Regeneron & Gilead, Makers Of COVID-19 Drugs He’s Now Taking

President Donald Trump has earned capital gains from Regeneron Pharmaceuticals and Gilead Sciences Inc., the two biotechnology companies that have created drugs that are aiding Trump in his COVID-19 treatment. Since being diagnosed last week, Trump has been given an eight-gram dose of Regeneron’s antiviral cocktail and is on a five-day treatment of Gilead Science’s Remdesivir.

According to a 2017 financial disclosure form that was filed with the U.S. Office of Government Ethics, Trump had a capital gain of $50,001 to $100,000 for Regeneron Pharmaceuticals and $100,001 to $1 million for Gilead Sciences Inc.

Regeneron’s chief executive and a member of Trump’s golf club in Westchester County, New York, Dr. Leonard S. Schleifer, said Trump’s medical staff reached out to the company for permission to use the Regeneron’s REGN-COV2 cocktail drug, and the Food and Drug Administration cleared it.

It was unclear Saturday whether Trump currently has any direct stakes in Regeneron and Gilead.